Silence Therapeutics (SLN) is having a moment. Shares jumped nearly 23% on Wednesday after Cantor Fitzgerald started covering the stock with an Overweight rating and a pretty compelling thesis: this $300 million biotech might be deeply mispriced.

The bullish case centers on divesiran, the company's lead candidate for polycythemia vera (PV), a rare, slow-growing blood cancer where the bone marrow goes into overdrive producing red blood cells. Cantor analyst Prakhar Agrawal thinks divesiran could become a major player in the PV market, and the upcoming Phase 2 data — expected in August 2026 — could be the spark that lights a fire under the stock.

The Dosing Advantage

PV patients currently have limited options. The most promising rival in development is rusfertide, a drug from Protagonist Therapeutics (PTGX) and Takeda (TAK), which recently nailed its Phase 3 VERIFY study, hitting the primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class hepcidin mimetic that's already earned FDA Orphan Drug and Fast Track designations.

But here's where divesiran could steal the show: dosing convenience. Rusfertide requires weekly injections. Divesiran, on the other hand, is being tested at every-6-week and every-12-week intervals. As Agrawal put it, "We are positive on the upcoming P2 PV trial and expect divesiran to show rusfertide-like efficacy while offering a meaningful dosing convenience advantage."

Cantor's checks with key opinion leaders suggest that even the every-6-week schedule could drive meaningful uptake, assuming comparable efficacy and safety. That's a big if, but the Phase 1 data was encouraging — a 100% response rate in well-controlled PV patients.

The Valuation Case

With a market cap of just $300 million, Silence Therapeutics looks cheap relative to the opportunity. Agrawal sees a 75% probability of success for the Phase 2 trial, and his valuation range implies over 160% upside from current levels. That's the kind of risk/reward that gets biotech investors excited.

"Risk/reward is very attractive for Phase 2," he wrote, and it's hard to argue. If divesiran delivers in August, the stock could re-rate significantly. If it stumbles, well, that's the biotech gamble.

Price Action

Shares of Silence Therapeutics closed at $8.93 on Wednesday, up 22.9% and hitting a new 52-week high. The market is clearly paying attention. Whether the August data will justify the hype — or the analyst's optimism — remains to be seen. But for now, the story is compelling.